Great Valley Advisor Group Inc. Purchases 61 Shares of Danaher Co. (NYSE:DHR)

Great Valley Advisor Group Inc. lifted its holdings in Danaher Co. (NYSE:DHR) by 3.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,646 shares of the conglomerate’s stock after acquiring an additional 61 shares during the period. Great Valley Advisor Group Inc.’s holdings in Danaher were worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. nVerses Capital LLC acquired a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the second quarter worth $25,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the third quarter valued at $40,000. Darwin Wealth Management LLC bought a new stake in Danaher in the third quarter valued at $55,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter worth about $51,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. KeyCorp upped their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Barclays cut their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 18th. Stifel Nicolaus upped their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Finally, Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Performance

NYSE:DHR opened at $236.53 on Wednesday. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a fifty day simple moving average of $256.66 and a two-hundred day simple moving average of $259.81. The company has a market capitalization of $170.84 billion, a P/E ratio of 45.14, a P/E/G ratio of 4.34 and a beta of 0.85.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 EPS. On average, analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. Danaher’s dividend payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.